ASH Annual Meeting and Exposition | Conference

Updated Study Results Show Durable Responses in CLL After Fixed-Duration Ibrutinib-Venetoclax Based on Undetectable MRD

December 11th 2021

The use of ibrutinib plus venetoclax in the first-line setting for patients with previously untreated chronic lymphocytic leukemia continues to provide deep, durable responses, according to updated results from the MRD cohort of the phase 2 CAPTIVATE trial.

Dr. Kamdar on the Results of the TRANSFORM Trial in Relapsed/Refractory LBCL

December 11th 2021

Manali Kamdar, MD, discusses the results of the phase 3 TRANSFORM trial in relapsed/refractory large B-cell lymphoma (LBCL) that were presented during the 2021 ASH Annual Meeting & Exposition.

Frontline Venetoclax-Based Combos Improve uMRD Rates Vs Chemoimmunotherapy in Fit Patients With CLL

December 11th 2021

The combination of obinutuzumab and venetoclax (GVe), as well as GVe plus ibrutinib demonstrated superior rates of undetectable minimal residual disease compared with chemoimmunotherapy in fit patients with chronic lymphocytic leukemia, according to findings from the phase 3 GAIA (CLL13) trial.

Frontline Ibrutinib/Venetoclax Induces Higher MRD Clearance and Fewer Relapses in Elderly and Unfit CLL

December 11th 2021

Frontline fixed-duration treatment with ibrutinib plus venetoclax led to deeper and prolonged rates of undetectable minimal residual disease in the bone marrow and peripheral blood, leading to fewer relapses in the first year post-treatment vs chlorambucil plus obinutuzumab in elderly and unfit patients with chronic lymphocytic leukemia.

MRD-Guided Ibrutinib Plus Venetoclax Demonstrates Feasibility in Relapsed/Refractory CLL

December 11th 2021

The minimal residual disease–guided combination of ibrutinib plus venetoclax was found to be a feasible treatment regimen for patients with relapsed/refractory chronic lymphocytic leukemia.

Orca-T Shows Impressive Clinical Outcomes in High-Risk Hematological Cancers

December 11th 2021

Orca-T significantly improved graft-vs-host disease–free relapse-free survival and time to engraftment, significantly reduced acute and chronic GVHD, and showed a trend toward improved overall survival vs standard of care in patients with serious hematologic malignancies

Daratumumab Combos Showcase Superior Survival in First- Vs Second-Line Settings in Transplant-Ineligible Multiple Myeloma

December 11th 2021

Daratumumab, lenalidomide, and dexamethasone demonstrated an overall survival advantage in the first-line setting compared with the same agents in the second-line setting in patients with transplant-ineligible multiple myeloma.

Mosunetuzumab Represents Effective Option for Heavily Pretreated Relapsed/Refractory Follicular Lymphoma

December 11th 2021

Fixed-duration treatment with the bispecific antibody mosunetuzumab induced deep and durable responses with favorable tolerability in heavily pretreated patients with relapsed or refractory follicular lymphoma, meeting the primary end point of the ongoing phase 1/2b GO29781 trial.

Ixazomib/Daratumumab Showcases Favorable Safety in Elderly Frail Patients With Relapsed/Refractory Myeloma

December 11th 2021

The combination of daratumumab plus ixazomib, without dexamethasone, was found to have a favorable safety profile in very elderly frail patients with relapsed or refractory multiple myeloma and high cytogenetic risk.

Liso-cel Bests Standard of Care in Second-Line Treatment of LBCL

December 11th 2021

Lisocabtagene maraleucel demonstrated statistically and clinically meaningful improvement in event-free survival compared with the standard of care as a second-line therapy in patients with relapsed or refractory large B-cell lymphoma.

Less-Toxic Ixazomib/Daratumumab Combo Attempted for Intermediate-Fit, Non-Transplant Eligible Newly Diagnosed Multiple Myeloma

December 11th 2021

The combination of ixazomib, daratumumab, and low-dose dexamethasone elicited an objective response rate of 71% in non-transplant eligible, intermediate-fit patients with newly diagnosed multiple myeloma.

Liso-cel Improves HRQoL Over Standard of Care in Relapsed/Refractory LBCL

December 9th 2021

Second-line lisocabtagene maraleucel demonstrated a favorable improvement in most patient-reported outcome domains compared with standard of care in patients with relapsed or refractory large B-cell lymphoma, and health-related quality of life was found to either be improved or maintained following treatment with the CAR T-cell therapy.

ASH 2021 Is Packed With Practice-Changing Hematologic Cancer Data

December 9th 2021

Not only is the 2021 ASH Annual Meeting bursting with more than 5000 abstracts unveiling pivotal data across a range of hematologic malignancies and disorders, but the conference will be held as a hybrid format after going fully virtual in 2020.

Liso-cel Significantly Prolongs EFS Over SOC in Second-Line Relapsed/Refractory LBCL

December 3rd 2021

Lisocabtagene maraleucel significantly prolonged event-free survival and progression-free survival and improved complete responses when used in the second-line treatment of patients with relapsed or refractory large B-cell lymphoma.

Lisocabtagene Maraleucel Displays Durable Remissions in Relapsed/Refractory LBCL

November 29th 2021

Lisocabtagene maraleucel demonstrated durable responses and a favorable safety profile in patients with relapsed/refractory large B-cell lymphoma.

Higher Dose of CPX-351 Linked With Prolonged Hematologic Recovery in AML

December 9th 2020

CPX-351, when given at higher doses in induction cycles 1 and 2, significantly prolonged hematologic recovery in younger patients with newly diagnosed high-risk or secondary acute myeloid leukemia.

Dr. Lin on Updated Results of the CRB-401 Trial in Relapsed/Refractory Multiple Myeloma

December 8th 2020

Yi Lin, MD, PhD, discussess updated results of the phase 1 CRB-401 study in relapsed/refractory multiple myeloma.

Dr. Zeiser on Results of the REACH3 Trial in Chronic GVHD

December 8th 2020

Robert Zeiser, MD, discusses results of the REACH3 trial in chronic graft-versus-host disease.

TRPH-222 Shows Early Antitumor Activity, Tolerability in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

December 8th 2020

The antibody-drug conjugate TRPH-222 demonstrated early signs of efficacy with favorable tolerability at higher dose levels in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.

Brentuximab Vedotin Shows Encouraging Responses Rates, Tolerability in Older Patients With Hodgkin Lymphoma

December 8th 2020

December 8, 2020 — The antibody-drug conjugate brentuximab vedotin demonstrated high response rates with durability, as well as a tolerable safety profile among older patients with comorbid classical Hodgkin lymphoma.